Reports
Sale
Tay-Sachs Disease Market Size, Trends, Report: By Drug Type; Anticonvulsants, Antipsychotic Medications, Others; By Type: Infantile Tay-Sachs Disease, Juvenile Tay-Sachs Disease, Late-Onset Tay-Sachs Disease; By Treatment; By Route of Administration; By Distribution Channel; By End User; Regional Analysis; Supplier Landscape; 2024-2032
Tay-Sachs Disease Market Outlook
The Tay-Sachs disease market size was valued at USD 2.3 billion in 2023, driven by the rising advancements in stem cell therapies across the major markets. The market is expected to grow at a CAGR of 5.6% during the forecast period of 2024-2032, with the values likely to rise from USD 2.5 billion in 2024 to USD 3.83 billion by 2032.
Tay-Sachs Disease: Introduction
Tay-Sachs disease is a rare genetic condition that affects a child’s nerve cells in the brain and spinal cord. It is caused by the absence of an enzyme that helps break down fatty substances (also known as gangliosides). These substances build up to toxic levels and affect the impact the nerve cell functions. Early symptoms of the disease appear at about 3-6 months of age. The muscle development slows down and the child may experience seizures as well.
Tay-Sachs Disease Market Analysis
The Tay-Sachs disease market value is driven by the rising emphasis on mitigating the morbidities associated with the disease, which includes the development of new therapeutics and improving the existing system for improved results. AAV (adeno-associated virus) gene therapy is one of the latest therapies being investigated. It impacted the HexA activity which increased from the baseline and remained stable in patients.
In addition, there has been a significant development in other therapies as well, which includes enzyme replacement therapy, substrate reduction therapy, hematopoietic stem cell transplantation, gene therapies. The market growth is also driven by rising investments and grants for innovative treatment alternatives. The California Institute for Regenerative Medicine (CIRM) has invested a hefty sum of USD 4 million into UC Davis researchers to establish a stem cell gene therapy to treat the condition.
With a key focus on developing a genetic cure for GM2 gangliosidosis (including Tay-Sachs disease), several companies and organizations are collaborating to investigate and develop better therapies. In June 2023, New Hope Research Foundation and Forge Biologics partnered for the cGMP manufacturing to enhance the Foundation's NHR01, a novel gene therapy. Such collaborations are essential to meet the rising Tay-Sachs disease market demand and expected to boost market growth further in the coming years.
Tay-Sachs Disease Market Segmentation
Market Breakup by Drug Type
- Anticonvulsants
- Antipsychotic Medications
- Others
Market Breakup by Type
- Infantile Tay - Sachs Disease
- Juvenile Tay-Sachs Disease
- Late-Onset Tay-Sachs Disease
Market Breakup by Treatment
- Medication
- Respiratory Care
- Physical Therapy
Market Breakup by Route of Administration
- Injectable
- Oral
- Others
Market Breakup by Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Market Breakup by End User
- Hospitals
- Homecare
Market Breakup by Region
- United States
- EU-4 and the United Kingdom
- Germany
- France
- Italy
- Spain
- United Kingdom
- Japan
Tay-Sachs Disease Market Overview
Early screening during pregnancy is a key method to prevent genetic disorders in children. As a result, pregnancy screenings are considered highly critical nowadays. In the historical period, the condition has been more prevalent in Central and Eastern European Jewish ancestry, therefore, Europe has led the Tay-Sachs disease market share. Having a robust healthcare, along with academic institutions, there have been significant enhancements to decrease the rising burden of the disease.
In North America, the United States is a major market with a heavy focus on disease detection at the pregnancy stage. Organizations such as JScreen have set up campaigns and have been actively encouraging people to undergo testing for genetic diseases. In the case of in-vitro fertilization, preimplantation genetic testing is widely applied.
Asia Pacific is expected to witness exponential Tay-Sachs disease market growth, with increasing medical and research advancements occurring in the region. Mergers and acquisitions between native and international corporations is further fostering the market growth in the region. In addition, foreign investments to put the easy availability of resources to use are also impacting the market positively.
Tay-Sachs Disease Market: Competitor Landscape
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
- Recursion Pharmaceuticals, Inc.
- IntraBioInc
- Johnson & Johnson Services
- Axovant Sciences, Inc.
- Pfizer
- Sio Gene Therapies Ltd
- F. Hoffmann-La
- Roche Ltd
- Bayer AG
- Bausch Health
- Boehringer Ingelheim International GmbH
Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
| Base Year | 2023 |
| Historical Period | 2017-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Drug Type |
|
| Breakup by Type |
|
| Breakup by Treatment |
|
| Breakup by Route of Administration |
|
| Breakup by Distribution Channel |
|
| Breakup by End User |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Competitive Landscape |
|
| Companies Covered |
|
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Tay-Sachs Disease Overview
3.1 Guidelines and Stages
3.2 Pathophysiology
3.3 Screening and Diagnosis
3.4 Treatment Pathway
4 Patient Profile
4.1 Patient Profile Overview
4.2 Patient Psychology and Emotional Impact Factors
4.3 Risk Assessment and Treatment Success Rate
5 Tay-Sachs Disease Epidemiology Analysis – 7MM
5.1 7MM Epidemiology Scenario Overview (2017-2032)
5.2 United States Tay-Sachs Disease Epidemiology Forecast (2017-2032)
5.3 EU-4 and United Kingdom Tay-Sachs Disease Epidemiology Forecast (2017-2032)
5.3.1 Germany Tay-Sachs Disease Epidemiology Forecast (2017-2032)
5.3.2 France Tay-Sachs Disease Epidemiology Forecast (2017-2032)
5.3.3 Italy Tay-Sachs Disease Epidemiology Forecast (2017-2032)
5.3.4 Spain Tay-Sachs Disease Epidemiology Forecast (2017-2032)
5.3.5 United Kingdom Tay-Sachs Disease Epidemiology Forecast (2017-2032)
5.4 Japan Tay-Sachs Disease Epidemiology Forecast (2017-2032)
6 Tay-Sachs Disease Market Overview – 7MM
6.1 Tay-Sachs Disease Market Historical Value (2017-2023)
6.2 Tay-Sachs Disease Market Forecast Value (2024-2032)
7 Tay-Sachs Disease Market Landscape – 7MM
7.1 Tay-Sachs Disease Developers Landscape
7.1.1 Analysis by Year of Establishment
7.1.2 Analysis by Company Size
7.1.3 Analysis by Region
7.2 Tay-Sachs Disease Product Landscape
7.2.1 Analysis by Diseases Type
7.2.2 Analysis by Treatments
7.2.3 Analysis by Route of Administration
8 Tay-Sachs Disease Challenges and Unmet Needs
8.1 Treatment Pathway Challenges
8.2 Compliance and Drop-Out Analysis
8.3 Awareness and Prevention Gaps
9 Cost of Treatment
10 Tay-Sachs Disease Market Dynamics
10.1 Market Drivers and Constraints
10.2 SWOT Analysis
10.3 Porter’s Five Forces Model
10.4 Key Demand Indicators
10.5 Key Price Indicators
10.6 Industry Events, Initiatives, and Trends
10.7 Value Chain Analysis
11 Tay-Sachs Disease Market Segmentation – 7MM
11.1 Tay-Sachs Disease Market by Drug Type
11.1.1 Market Overview
11.1.2 Anticonvulsants
11.1.3 Antipsychotic Medications
11.1.4 Others
11.2 Tay-Sachs Disease Market by Type
11.2.1 Market Overview
11.2.2 Infantile Tay - Sachs Disease
11.2.3 Juvenile Tay-Sachs Disease
11.2.4 Late-Onset Tay-Sachs Disease
11.3 Tay-Sachs Disease Market by Treatment
11.3.1 Market Overview
11.3.2 Medication
11.3.3 Respiratory Care
11.3.4 Physical Therapy
11.4 Tay-Sachs Disease Market by Route of Administration
11.4.1 Market Overview
11.4.2 Injectable
11.4.3 Oral
11.4.4 Others
11.5 Tay-Sachs Disease Market by Distribution Channel
11.5.1 Market Overview
11.5.2 Hospital Pharmacies
11.5.3 Retail Pharmacies
11.5.4 Online Pharmacies
11.6 Tay-Sachs Disease Market by End User
11.6.1 Market Overview
11.6.2 Hospitals
11.6.3 Homecare
11.7 Tay-Sachs Disease Market by Region
11.7.1 Market Overview
11.7.2 United States
11.7.3 EU-4 and the United Kingdom
11.7.3.1 Germany
11.7.3.2 France
11.7.3.3 Italy
11.7.3.4 Spain
11.7.3.5 United Kingdom
11.7.4 Japan
12 United States Tay-Sachs Disease Market
12.1 Tay-Sachs Disease Market Historical Value (2017-2023)
12.2 Tay-Sachs Disease Market Forecast Value (2024-2032)
12.3 Tay-Sachs Disease Market by Drug Type
12.4 Tay-Sachs Disease Market by Treatment Type
13 EU-4 and United Kingdom Tay-Sachs Disease Market
13.1 Tay-Sachs Disease Market Historical Value (2017-2023)
13.2 Tay-Sachs Disease Market Forecast Value (2024-2032)
13.3 Germany Tay-Sachs Disease Market Overview
13.3.1 Tay-Sachs Disease Market by Drug Type
13.3.2 Tay-Sachs Disease Market by Treatment Type
13.4 France Tay-Sachs Disease Market Overview
13.4.1 Tay-Sachs Disease Market by Drug Type
13.4.2 Tay-Sachs Disease Market by Treatment Type
13.5 Italy Tay-Sachs Disease Market Overview
13.5.1 Tay-Sachs Disease Market by Drug Type
13.5.2 Tay-Sachs Disease Market by Treatment Type
13.6 Spain Tay-Sachs Disease Market Overview
13.6.1 Tay-Sachs Disease Market by Drug Type
13.6.2 Tay-Sachs Disease Market by Treatment Type
13.7 United Kingdom Tay-Sachs Disease Market Overview
13.7.1 Tay-Sachs Disease Market by Drug Type
13.7.2 Tay-Sachs Disease Market by Treatment Type
14 Japan Tay-Sachs Disease Market
14.1 Tay-Sachs Disease Market Historical Value (2017-2023)
14.2 Tay-Sachs Disease Market Forecast Value (2024-2032)
14.3 Tay-Sachs Disease Market by Drug Type
14.4 Tay-Sachs Disease Market by Treatment Type
15 Patent Analysis
15.1 Analysis by Type of Patent
15.2 Analysis by Publication year
15.3 Analysis by Issuing Authority
15.4 Analysis by Patent Age
15.5 Analysis by CPC Analysis
15.6 Analysis by Patent Valuation
15.7 Analysis by Key Players
16 Grants Analysis
16.1 Analysis by year
16.2 Analysis by Amount Awarded
16.3 Analysis by Issuing Authority
16.4 Analysis by Grant Application
16.5 Analysis by Funding Institute
16.6 Analysis by NIH Departments
16.7 Analysis by Recipient Organization
17 Clinical Trials Analysis
17.1 Analysis by Trial Registration Year
17.2 Analysis by Trial Status
17.3 Analysis by Trial Phase
17.4 Analysis by Therapeutic Area
17.5 Analysis by Geography
18 Funding and Investment Analysis
18.1 Analysis by Funding Instances
18.2 Analysis by Type of Funding
18.3 Analysis by Funding Amount
18.4 Analysis by Leading Players
18.5 Analysis by Leading Investors
18.6 Analysis by Geography
19 Partnership and Collaborations Analysis
19.1 Analysis by Partnership Instances
19.2 Analysis by Type of Partnership
19.3 Analysis by Leading Players
19.4 Analysis by Geography
20 Supplier Landscape
20.1 Recursion Pharmaceuticals, Inc.
20.1.1 Financial Analysis
20.1.2 Product Portfolio
20.1.3 Demographic Reach and Achievements
20.1.4 Mergers and Acquisition
20.1.5 Certifications
20.2 IntraBioInc
20.2.1 Financial Analysis
20.2.2 Product Portfolio
20.2.3 Demographic Reach and Achievements
20.2.4 Mergers and Acquisition
20.2.5 Certifications
20.3 Johnson & Johnson Services
20.3.1 Financial Analysis
20.3.2 Product Portfolio
20.3.3 Demographic Reach and Achievements
20.3.4 Mergers and Acquisition
20.3.5 Certifications
20.4 Axovant Sciences, Inc.
20.4.1 Financial Analysis
20.4.2 Product Portfolio
20.4.3 Demographic Reach and Achievements
20.4.4 Mergers and Acquisition
20.4.5 Certifications
20.5 Pfizer
20.5.1 Financial Analysis
20.5.2 Product Portfolio
20.5.3 Demographic Reach and Achievements
20.5.4 Mergers and Acquisition
20.5.5 Certifications
20.6 Sio Gene Therapies Ltd
20.6.1 Financial Analysis
20.6.2 Product Portfolio
20.6.3 Demographic Reach and Achievements
20.6.4 Mergers and Acquisition
20.6.5 Certifications
20.6.6 F. Hoffmann-La
20.7 Roche Ltd
20.7.1 Financial Analysis
20.7.2 Product Portfolio
20.7.3 Demographic Reach and Achievements
20.7.4 Mergers and Acquisition
20.7.5 Certifications
20.8 Bayer AG
20.8.1 Financial Analysis
20.8.2 Product Portfolio
20.8.3 Demographic Reach and Achievements
20.8.4 Mergers and Acquisition
20.8.5 Certifications
20.9 Bausch Health
20.9.1 Financial Analysis
20.9.2 Product Portfolio
20.9.3 Demographic Reach and Achievements
20.9.4 Mergers and Acquisition
20.9.5 Certifications
20.10 Boehringer Ingelheim International GmbH
20.10.1 Financial Analysis
20.10.1 Product Portfolio
20.10.2 Demographic Reach and Achievements
20.10.3 Mergers and Acquisition
20.10.4 Certifications
21 Tay-Sachs Disease Market - Distribution Model (Additional Insight)
21.1 Overview
21.2 Potential Distributors
21.3 Key Parameters for Distribution Partner Assessment
22 Key Opinion Leaders (KOL) Insights (Additional Insight)
23 Company Competitiveness Analysis (Additional Insight)
23.1 Very Small Companies
23.2 Small Companies
23.3 Mid-Sized Companies
23.4 Large Companies
23.5 Very Large Companies
24 Payment Methods (Additional Insight)
24.1 Government Funded
24.2 Private Insurance
24.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
Key Questions Answered in the Report
The market attained a value of about USD 2.3 billion in 2023, driven by the rising advancements in stem cell therapies across the 7 major markets.
The market is anticipated to grow at a CAGR of 5.6% during the forecast period of 2024-2032, likely to reach a market value of USD 3.83 billion by 2032.
The market demand is driven by the heavy emphasis on early detection of the condition with the help of genetic testing tools.
The market trend involves increasing collaborations between organizations to find quality therapeutics for the condition. In June 2023, New Hope Research Foundation and Forge Biologics collaborated to manufacture cGMP to enhance the Foundation's NHR01, a novel gene therapy.
Based on types, the market is divided into infantile Tay-Sachs disease, juvenile Tay-Sachs disease, and late-onset Tay-Sachs disease.
Medication, respiratory care, and physical therapy are common treatments available in the market.
Anticonvulsants and antipsychotic medications, among others are the common drug types.
Major distribution channels include hospital pharmacies, retail pharmacies, and online pharmacies.
Major end users in the market include hospitals and homecare.
The route of administration can be oral and/or injectable, among others.
The major regions of the market include the United States, Japan, EU-4 which is segmented into Germany, France, Italy, Spain, and the United Kingdom.
Key players involved in the market are Recursion Pharmaceuticals, Inc., IntraBioInc, Johnson & Johnson Services, Axovant Sciences, Inc., Pfizer, Sio Gene Therapies Ltd., F. Hoffmann-La, Roche Ltd., Bayer AG, Bausch Health, and Boehringer Ingelheim International GmbH.
Purchase Options 10% off
Call us
Purchase Full Report
Mini Report
$ 3299
$2999
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Single User License
$ 6599
$5999
-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Five User License
$ 8799
$7999
-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$ 9899
$8999
-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Why Expert Market Research?
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
NEWSLETTER